Which medications are used to treat obsessive‑compulsive disorder (OCD)?

Medications for OCD Treatment

Selective serotonin reuptake inhibitors (SSRIs) are the first-line medications for OCD, requiring higher doses than depression treatment: fluoxetine 60-80 mg daily, sertraline 150-200 mg daily, paroxetine 60 mg daily, fluvoxamine 200-300 mg daily, or escitalopram 20 mg daily. 1, 2

First-Line SSRI Treatment

The following SSRIs are recommended as initial pharmacological treatment due to their efficacy, tolerability, safety, and lack of abuse potential 1:

• Fluoxetine: 60-80 mg daily (superior safety profile in pediatric populations) 1, 2
• Sertraline: 150-200 mg daily (faster onset of clinical improvement and higher early remission rates compared to fluoxetine) 2
• Paroxetine: 60 mg daily (FDA-approved for OCD, though higher discontinuation syndrome risk) 1
• Fluvoxamine: 200-300 mg daily 3, 4
• Escitalopram: 20 mg daily 1

Critical Dosing Principles

• OCD requires substantially higher SSRI doses than depression or other anxiety disorders 1, 2
• Allow 8-12 weeks at maximum tolerated dose before declaring treatment failure, with maximal improvement typically by week 12 or later 1, 2
• Early response by weeks 2-4 predicts ultimate treatment success 1, 2
• Maintain treatment for minimum 12-24 months after achieving remission due to high relapse risk after discontinuation 1, 2, 4

Second-Line Treatment: Clomipramine

Clomipramine 150-250 mg daily is reserved for patients who fail at least one adequate SSRI trial, despite potential superior efficacy, due to inferior safety and tolerability profile 1, 3. This tricyclic antidepressant has prevalent serotonergic activity and robust evidence for OCD treatment 5, 6, 4.

Treatment-Resistant OCD: Augmentation Strategies

When SSRIs fail after adequate trials (maximum dose for 8-12 weeks), consider these evidence-based augmentation approaches:

Highest Priority: Add Cognitive Behavioral Therapy

Adding CBT with exposure and response prevention (ERP) produces larger effect sizes than medication augmentation alone, with approximately 41% symptom reduction in SSRI non-responders 2, 3, 4. Consistent completion of between-session ERP homework is the strongest predictor of favorable outcomes 3.

Antipsychotic Augmentation

Risperidone and aripiprazole (5-15 mg daily) have the strongest evidence for SSRI-resistant OCD, though only one-third of patients show clinically meaningful response 2, 3, 4. Monitor for metabolic side effects including weight gain, blood glucose, and lipid profiles 3.

Glutamatergic Agents

• N-acetylcysteine has the strongest evidence among glutamatergic agents, with 3 of 5 RCTs showing superiority to placebo 2, 3
• Memantine has demonstrated efficacy in multiple trials 2, 7
• Lamotrigine shows promise as augmentation 3, 7

Alternative Strategies

• Combining fluoxetine with clomipramine was superior to fluoxetine plus quetiapine in treatment-resistant OCD 2
• Switch to a different SSRI if augmentation fails, as individual responses vary 3

Advanced Interventions for Highly Refractory Cases

• Deep repetitive transcranial magnetic stimulation (rTMS) is FDA-approved for treatment-resistant OCD, with moderate therapeutic effect (effect size = 0.65) and 3-fold increased likelihood of response versus sham 3, 4
• Deep brain stimulation (DBS) targeting bilateral subthalamic nucleus has Level I evidence for medically refractory OCD 3, 4

Critical Safety Considerations

Pharmacogenetic Testing

Consider CYP2D6 testing before high-dose fluoxetine or paroxetine, as poor metabolizers have 3.9-fold to 11.5-fold higher drug exposure with significantly increased toxicity risk, including QT prolongation and documented fatal cases 1, 2.

Avoid Common Pitfalls

• Never conclude treatment resistance without documenting at least one adequate trial (proper dose for 8-12 weeks with confirmed adherence) 3
• Do not switch medications based on early side effects or lack of response before week 8-12 3
• Benzodiazepines may impede ERP progress by preventing the habituation essential to exposure therapy and should be avoided 3
• Inadequate dose or duration creates a cycle of apparent "nonresponse" leading to unnecessary medication switches 3

Drug Interactions

• Fluoxetine is a potent CYP2D6 inhibitor that converts approximately 43% of extensive metabolizers to poor metabolizer phenotype, creating significant drug-drug interaction risks 1, 2
• Both SSRIs and clomipramine are contraindicated with MAOIs due to serotonin syndrome risk 1